The Japanese encephalitis virus (JEV) is the most common cause of neurodegenerative disease in Southeast Asia and the Western Pacific region; approximately 1.15 billion people are at risk, and thousands suffer from permanent neurological disorders across Asian countries, with 10–15 thousand people dying each year. JEV crosses the blood-brain barrier (BBB) and forms a complex with receptors on the surface of neurons. GRP78, Src, TLR7, caveolin-1, and dopamine receptor D2 are involved in JEV binding and entry into the neurons, and these receptors also play a role in carcinogenic activity in cells. JEV binds to GRP78, a member of the HSP70 overexpressed on malignant cells to enter neurons, indicating a higher chance of JEV infection in cancer patients. However, JEV enters human brain microvascular endothelial cells via an endocytic pathway mediated by caveolae and the ezrin protein and also targets dopamine-rich areas for infection of the midbrain via altering dopamine levels. In addition, JEV complexed with CLEC5A receptor of macrophage cells is involved in the breakdown of the BBB and central nervous system (CNS) inflammation. CLEC5A-mediated infection is also responsible for the influx of cytokines into the CNS. In this review, we discuss the neuronal and macrophage surface receptors involved in neuronal death.
Context: Swietenia mahagoni L. Jacq. (Meliaceae) is a medium to large evergreen tree native to Southern Florida, Cuba, The Bahamas, Hispaniola, and Jamaica. Objective: To evaluate the antidiabetic and antioxidant potential of S. mahagoni bark. Materials and methods: In the present study, the antidiabetic activity of the methanol extract of S. mahagoni (MESM) bark in streptozotocin (STZ; 65 mg/kg body weight)-induced diabetic rats was evaluated. Glibenclamide (0.5 mg/kg; orally) was taken as the reference drug. The blood glucose levels and body weights were measured every 5th day over a period of 15 days. Antioxidant effects were assayed in diabetic rats by estimating thiobarbituric acid reactive substances (TBARS), glutathione (GSH), and catalase (CAT) levels. Results and discussion: Oral administration of MESM at the doses of 25 and 50 mg/kg b.w. resulted in a significant (p < 0.001) reduction in blood glucose levels in diabetic rats. Body weights were significantly (p < 0.001) reduced in STZ-induced diabetic rats when compared to normal rats, while the extract significantly restored body weight. The present study was further undertaken to evaluate the antioxidant activity of MESM in STZ-induced diabetic rats. Decreased levels of TBARS and increased levels of GSH and CAT activity indicated a reduction in free radical formation in tissues such as the liver and kidney of diabetic rats. Conclusion: These findings showed the significant hypoglycemic and antioxidant activity of the extract (MESM) in diabetic rats.